Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLC022 (propentofylline) versus placebo in postherpetic neuralgia
2008-002108-24Phase 2Completed
- Sponsor
- Solace Pharmaceuticals
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing Propentofylline 300 mg TID with Placebo TID (2 arms). Started Jan 2009; status: completed.
02
Drugs
Propentofylline
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2008-002108-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002108-24.